US00773J2024
US00773J2024
Spyre Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 219.562.000 | 208.566.000 | 5.3% | |
| Operating Income | -219.562.000 | -208.566.000 | 5.3% |
| Pretax Income | -155.218.000 | -207.967.000 | 25.4% |
| Net Income Common Stockholders | -155.203.000 | -208.018.000 | 25.4% |
| -- | -- | -- | |
| -- | -- | -- |